home / stock / soltf / soltf short
Short Information | Sosei Co Ltd Ord (OTCMKTS:SOLTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 36,365 |
Total Actual Volume | 64,088 |
Short Trends | |
---|---|
Cover Days | 7 |
Short Days | 12 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,818 |
Average Short Percentage | 63.96% |
Is there a SOLTF Short Squeeze or Breakout about to happen?
See the SOLTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-16-2024 | $9.72 | $9.72 | $9.72 | $9.72 | 100 | 100 | 100% |
04-08-2024 | $10.44 | $10.44 | $10.44 | $10.44 | 300 | 300 | 100% |
03-13-2024 | $10.7461 | $10.7461 | $10.7461 | $10.7461 | 465 | 465 | 100% |
03-11-2024 | $11.88 | $13.43 | $13.43 | $11.71 | 50,102 | 30,500 | 60.88% |
02-15-2024 | $8.56 | $8.65 | $8.715 | $8.56 | 1,500 | 100 | 6.67% |
02-14-2024 | $9.5 | $9.5 | $9.5 | $9.5 | 500 | 500 | 100% |
01-29-2024 | $9.81 | $9.822 | $9.822 | $9.75 | 300 | 100 | 33.33% |
01-10-2024 | $10.5 | $10.89 | $10.89 | $10.5 | 2,303 | 200 | 8.68% |
12-15-2023 | $10.2 | $9.95 | $10.2 | $9.95 | 300 | 100 | 33.33% |
12-14-2023 | $10.17 | $10.17 | $10.17 | $10.17 | 1,000 | 1,000 | 100% |
12-04-2023 | $9.708 | $9.48 | $9.708 | $9.48 | 1,100 | 200 | 18.18% |
11-22-2023 | $10 | $10 | $10 | $10 | 500 | 500 | 100% |
10-24-2023 | $9.15 | $9.15 | $9.15 | $9.15 | 100 | 100 | 100% |
10-18-2023 | $9.38 | $9.45 | $9.45 | $9.38 | 350 | 150 | 42.86% |
10-13-2023 | $9.92 | $9.92 | $9.92 | $9.92 | 100 | 100 | 100% |
10-12-2023 | $9.86 | $9.91 | $9.91 | $9.86 | 2,000 | 1,000 | 50% |
10-03-2023 | $9.6 | $9.65 | $9.65 | $9.6 | 325 | 50 | 15.38% |
10-02-2023 | $10 | $9.6 | $10 | $9.6 | 2,043 | 200 | 9.79% |
09-26-2023 | $10.22 | $10.22 | $10.22 | $10.22 | 400 | 400 | 100% |
09-14-2023 | $10.65 | $10.65 | $10.65 | $10.65 | 300 | 300 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share Issuance”) under the...
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful completion of a long-term preclinical toxicity program to support safe, chronic dosing of NBI-1117568 in f...
PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH) PIVLAZ™ will become commercially available in South Korea in early 2025 Tokyo, Japan and Cambridge, UK, 1 5 April...